Pre and postjunctional effects of rosiglitazone on the isolated rat aorta and heart by Ferreira, Iolanda João Mora Cruz de Freitas
 Iolanda João Mora Cruz de Freitas Ferreira 
Pre- and postjunctional effect of rosiglitazone on the 
isolated rat aorta and heart 
2010/2011 
Abril, 2011 
  
Iolanda João Mora Cruz de Freitas Ferreira 
Pre- and postjunctional effect of rosiglitazone on the 
isolated rat aorta and heart 
Mestrado Integrado em Medicina 
 
Área: Farmacologia 
 
Trabalho efectuado sob a Orientação de: 
Prof. Prof. Doutor Daniel Moura 
e co-orientado por Prof. Doutor Hélder Pinheiro 
 
Baseado na revista Naunyn-Schmiedeberg´s Archives of Pharmacology 
Abril, 2011 
  
  
 
 1 
 
 
 
 
Pre- and postjunctional effect of rosiglitazone on the 
isolated rat aorta and heart 
 
 
 
 
 
 
 
 
 
 
 
 
I.Ferreira 
Faculdade de Medicina, Instituto de Farmacologia e Terapêutica, 
Alameda Hernâni Monteiro, 
4200-319 Porto, Portugal 
e-mail: med05206@med.up.pt 
Tel.: +351- 22-5513642 
Fax: +351 -22- 5513643 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
 
 
Abstract 
 
Rosiglitazone (RSG) increases the risk of ischemic cardiovascular events in type 2 
diabetes patients by unknown mechanisms. We determined the influence of RSG on the 
angiotensin II (AII)-mediated facilitation of noradrenaline release from sympathetic terminals 
(prejunctional effects) and on AII-mediated vasoconstriction (postjunctional effects). For 
comparison, of RSG influence on noradrenaline-mediated pre- and postjunctional effects was 
studied.  
In rat left ventricle isolated slices preloaded with 3H-noradrenaline and electrically 
stimulated, RSG (3 µM) caused a shift to the left of the concentration-response curve for the 
facilitatory effect of AII on tritium overflow.  The pEC30% values of AII in absence and presence 
of RSG (3 µM) were 8.6±0.1 and 9.3±0.3, respectively (n=5 each, P<0.05, t-test). Rauwolscine 
antagonized the autoreceptor-mediated negative feedback of noradrenaline release with a 
pEC30%=8.7±0.3 (n=4) in controls and a pEC30% =8.9±0.3, (n=4) in the presence of RSG. 
In rat aorta strips, RSG had no effect on the AII or noradrenaline-mediated 
vasoconstriction. For AII pEC50 was 7.2±0.4 and 7.6±0.5 and Emax was 132±39 and 129±35 
mN/g of tissue, n=3-5 each, in the absence and presence of RSG (3 µM), respectively.   For 
noradrenaline, pEC50 was 6.9±0.5 and 7.0±0.5 and Emax was 158±49 and 149±48, n=4 each, in 
the presence and absence of RSG, respectively. 
Data show that RSG selectively potentiates the prejunctional facilitatory effects of AII 
on sympathetic terminals. It is suggested that this increase in noradrenaline release might 
contribute to the cardiovascular harm of RSG. 
Key words: angiotensin II, rosiglitazone, noradrenaline release, cardiovascular, rat aorta
 3 
 
Resumo 
  
A rosiglitazona(RSG) aumenta o risco de eventos cardiovasculares isquémicos nos 
pacientes com diabetes mellitus tipo 2 por mecanismos desconhecidos. Determinamos a 
influência de RSG na facilitação da libertação de noradrenalina mediada pela angiotensina II 
(AII) nos terminais simpáticos (efeito pré-juncional) assim como na vasoconstrição mediada 
pela AII (efeito pós-juncional). Para comparação, estudamos a influência da RSG nos efeitos 
pré e pós-juncionais mediados pela noradrenalina. 
 
Em fatias isoladas de ventrículo esquerdo de rato carregado com3 H-noradrenalina e 
electricamente estimulado, RSG (3 µM) causou um desvio para a esquerda na curva de 
concentração-resposta para o efeito facilitatório da AII no fluxo tritiado. Os valores de pEC30% 
de AII na ausência e presença de RSG (3 µM) foram 8.6±0.1 e 9.3±0.3, respectivamente (n=5 
cada, P <0.05, t-test). A rauvolscina antagonizou o feedback negativo mediado por 
autoreceptores da liberação de noradrenalina com um pEC30% =8.7±0.3 (n=4) em controlos e um 
pEC30% = 8.9±0.3( n=4) na presença de RSG. 
 
Em tiras de aorta de rato, a RSG não teve efeito na vasoconstrição mediada tanto pela 
AII como pela noradrenalina. Para a AII o pEC50 foi de 7.2±0.4 e 7.6±0.5 e o Emax foi 132±39 e 
129±35 mN/g de tecido, n=3-5 cada, na ausência e na presença de RSG (3 µM), 
respectivamente. Para a noradrenalina, pEC50 foi 6.9±0.5 e 7.0±0.5 e o Emax foi 158±49 
e149±48, n=4 cada, na ausência e presença de RSG, respectivamente. 
 
Os resultados mostram que a RSG potencia selectivamente os efeitos pré-juncionais da 
AII nos terminais simpáticos. Podemos sugerir que este aumento de liberação de noradrenalina 
pode contribuir para os efeitos adversos cardiovasculares da RSG. 
Palavras -chave: angiotensina II, rosiglitazona, liberação de noradrenalina, cardiovascular, 
aorta de rato.
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Introduction 
 
RSG is an antidiabetic agent that targets the peroxisome-proliferator-activated receptor 
γ (PPARγ), a nuclear receptor that regulates the expression of many genes. RSG is an insulin 
sensitizer, improves glycemic control in type 2 diabetic patients and induces adipocyte 
differentiation. However, some studies point out several cardiovascular adverse effects 
produced by RSG, such as a significant increase in the risk of myocardial infarction and with an 
increase in the risk of death by other cardiovascular causes (Nissen and Wolski, 2010). Other 
studies now confirm the risk of developing heart failure with thiazolidinediones, namely in 
patients of all baseline cardiovascular risks, (diabetes mellitus, vascular disease or heart failure). 
(Chaggar et al., 2009).  
The PPARγ agonist RSG was recently withdrawn from the European market. The 
EMEA based this decision in the analysis of the RECORD trial, which showed that the addition 
of RSG to glucose-lowering therapy in people with type 2 diabetes increases the risk of heart 
failure, mainly in women (Home et al., 2009). Thiazolidinediones have cardiovascular effects 
through as yet poorly defined mechanisms (Higashi et al., 2010).  
The mechanism for the cardiovascular harm linked to RSG is uncertain. Recent 
experiments from our group (Bastos et al. 2008) showed that RSG and AT1-receptor antagonists 
had opposite effects on the prejunctional noradrenaline release-enhancing effect of AII. While 
AT1-receptor antagonists reduced, RSG increased the facilitatory action of AII on noradrenaline 
release by sympathetic nerve stimulation. This was unexpected because some of the AT1-
receptor antagonist tested mimetized the effect of RSG on adipocyte differentiation in vitro. It is 
known that telmisartan, a structurally unique AII receptor antagonist used for the treatment of 
hypertension, can function as a partial agonist of PPARγ; influence the expression of PPARγ 
target genes involved in carbohydrate and lipid metabolism; and reduce glucose, insulin, and 
triglyceride levels in rats fed a high-fat, high-carbohydrate diet (Benson et al., 2004). 
Since AII is a vasoconstrictor peptide that has a direct action on vascular smooth muscle 
cells and an indirect action mediated by facilitation of noradrenaline postganglionic sympathetic 
neurons, potentiation of AII might contribute to the increased cardiovascular risk associated 
with RSG. Cardiovascular diseases, like hypertension, cardiac heart failure and myocardial 
infarction depend on the activation of the sympathetic nervous system for their evolution 
(Sarafidis and Nilsson, 2006). 
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Other prejunctional studies have concluded that RSG increased the facilitatory action of 
AII on noradrenaline release in a concentration-dependent manner, without changing the 
release-enhancing effect of α2-autoreceptor antagonists in the rat heart. We also know that the 
potentiation of AII by RSG was antagonized by GW9662, a selective PPARγ antagonist. These 
results suggest that a positive allosteric modulation of AII receptors by PPARγ agonists may 
occur in sympathetic terminals (Ferreira et al, 2010). 
Nowadays, there are few studies that characterize the postjunctional effect of RSG in 
the AII modulating effects in the rat artery. Some studies demonstrated that RSG and 
pioglitazone treatment significantly restored the elevated systolic, mean arterial, diastolic blood 
pressure and attenuated the enhanced contractile responses to AII in thoracic aortic rings, and 
that pioglitazone and RSG significantly decreased the specific binding to AT1-receptors in high 
fat diet fed rats. It was concluded that the role of hyperglycemia in the elevation of AII induced 
vascular responses in thoracic aorta isolated from insulin resistant rats and PPARγ agonists can 
attenuate these responses (Gaikwad et al., 2007).  
Other studies conclude that RSG attenuated AII-induced blood pressure elevation and 
intracellular signaling on aorta and mesenteric vessels and that there was differential inhibition 
of AT1-receptor receptors/phosphatidylinositol 3-kinase/Akt and extracellular signal-regulated 
kinase 1/2 in both vessels. Effects of PPARγ activators on these pathways could contribute to 
regression of vascular remodeling in models of hypertension and diabetes and, accordingly, in 
hypertensive diabetic patients (Benkirane et al., 2006). Also, other postjunctional studies 
indicate that RSG, when acting on rat aorta, has beneficial effects in reducing blood pressure 
and the aortic tunica media hypertrophy with consequent balance of the wall stress in 
metabolically programmed offspring. In rats with a low protein diet, it restores the expressions 
of AT1-receptor and endothelial nitric oxide synthase nearly to the levels presented in rats with a 
normal protein diet (Torres et al., 2008). 
On the other hand, there are studies that indicate an endothelium-dependent mechanism 
of RSG and pioglitazone, which can alter vascular function differentially over the same 
pathways on the endothelium where they have a dual action, increasing both production of 
vasoconstrictor prostanoids and NO. The balance between both vasoactive substances 
determines the vascular response to TZD (Llorens et al., 2007).  
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The aim of this work is to characterize the pre and postjunctional effects of PPARγ 
agonist RSG on AII receptors of the rat heart and aorta, helping to clarify a possible explanation 
for the increase of mortality associated with cardiovascular causes inherent to RSG. For 
comparison, the influence of RSG on noradrenaline-mediated pre- and postjunctional effects 
was studied. 
 
 
 7 
 
Methods 
For the prejunctional studies the experiments were carried out in left ventricle slices. 
Male Wistar-Kyoto rats weighing 200-250 g were killed by decapitation, the heart was rapidly 
removed and the left ventricle isolated and cut in slices of about 7x7 mm. The slices were 
rapidly placed in warmed, aerated (with 95% O2 and 5% CO2) modified Krebs-Henseleit 
solution containing 3H-noradrenaline (0.2 µM) and agitated for 1 hour (incubation period). The 
referred Krebs- Henseleit solution had the following composition (mM): NaCl 119, CaCl2 2.52, 
KH2PO4 1.18, MgSO4 1.23, NaHCO3 25.0, glucose 10.0 (Mota and Guimaraes, 2003). 
After incubation, the slices were mounted in perifusion chambers and perifused with 
Krebs-Henseleit solution, warmed at 37° C, aerated with 95% O2 and 5% CO2, for 1 hour at a 
flow rate of 0.8 ml/min. Then the perifusing solution was changed to Krebs-Henseleit solution 
containing cocaine (12 µM), with the other conditions remaining the same, and the tissues were 
perifused for 20 more minutes. 
From t=80 min (t=0 being the onset of the perifusion) the perifusion fluid was collected 
continuously in samples of 5 min, during 100 min (a total of 20 samples).  
In the experiments using AII, three periods of transmural electric stimulation (1 Hz, 
2ms, 50 mA) during 5 min were applied at min 70 (S0), 100 (S1) and 150 (S2). The first period 
was not considered for the calculations; the second was taken as control (Scontrol) and the third 
was used to verify the influence of angiotensin on noradrenaline release (Sdrug). 
In the experiments using rauwolscine, two further periods of transmural electric 
stimulation were applied at min 200 (S3) and 250 (S4). Rauwolscine was added at increasing 
concentrations before S2, S3 and S4 (Sdrug). Drugs were added to the perifusion fluid at t=125 
min and were maintained until the end of the experience. 
At the end of experiment, the tissues were weighted and kept in perchloric acid (2 ml at 
0.2 M). Radioactivity was measured by scintillation counting (liquid scintillation counter 1209 
Rackbeta; LKB Wallac, Turku, Finland) in aliquots with the perifusate after addition of 8 ml of 
scintillation mixture (Wallac OptiPhase “HiSafe” 3; Fischer Chemicals, Loughborough, UK). 
The outflow of tritium was calculated as a fraction of the amount of tritium in the tissue 
at the start of the respective collection period (fractional rate of loss-1). The fractional release per 
shock was calculated by dividing evoked tritium overflow by tritium present in the tissue at the 
beginning of the stimulation period and by the number of shocks. Drug effects are expressed as 
the ratio FR of tritium evoked by Scontrol over that evoked by Sdrug. Each result was corrected for 
time-dependent changes as determined in parallel drug-free control experiments. 
For the calculation of the overflow induced by electrical stimulation those 5 min 
samples were taken into account in which the overflow of tritium exceeded that in the last 
prestimulation control sample (usually this applied to the 3 or 4 samples collected during and 
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after stimulation). The spontaneous outflow measured in the last pre-stimulation sample was 
assumed to represent the spontaneous outflow in subsequent samples; it was subtracted from the 
overflow determined in stimulation and post-stimulation samples. The  ‘total overflow of 
transmitter’ was the sum of all increases (induced by a period of stimulation) above the 
spontaneous level of outflow of tritium. 
 
For the postjunctional studies, a segment of the thoracic and abdominal aorta between 
the aortic arch and the bifurcation of the abdominal aorta into the femoral arteries was dissected 
and placed in Krebs-Henseleit solution without EDTA. After removing the excess fat, 
connective tissue and endothelium, the aorta was cut into helical strips approximately 2–3 mm 
in width and 15– 20 mm in length.  
The artery strips were mounted in a 10-ml bath containing aerated modified Krebs-
Henseleit solution at 37° for 1 h under a resting tension of 1.0 g. The mechanical responses were 
recorded on a Harvard Universal Oscillograph.  
Concentration-response curves were obtained on each strip by non-cumulative additions 
of AII with half-log increments. After the response to a given concentration had reached the 
maximum, the tissue was repeatedly washed out. Each postjunctional experiment consisted of: 
(a) a complete concentration-response curve of AII without RSG and (b) a complete 
concentration-response curve of AII in the presence of 3µM RSG.  
 
 
 
Statistics 
 
 EC30% values represent the molar concentration of the drug under study that increased 
the evoked overflow by 30% and pEC30% the negative logarithm of EC30%. pEC50 values 
represent the negative logarithm of the molar concentration of the agonist that causes 50% of 
the maximal contraction. The results are expressed as arithmetic means ±SEM, unless it is stated 
otherwise. A probability level of 0.05 was considered statistically significant (independent t-test 
with Newman-Keuls correction for multiple comparisons was used for statistical analyses). 
Curve fitting was done with the software GraphPad Prism (GraphPad Prism Software Inc., La 
Jolla, CA, USA). 
 
Chemicals 
The chemicals used in this study were: angiotensin II (Sigma, St. Louis, MO., USA); 
cocaine hydrochloride (Uquipa, Lisbon, Portugal); levo-[ring-2,5,6-3H]-noradrenaline (49.5 
Ci/mmol; PerkinElmer, Boston, MA., USA); L-(-)noradrenaline bitartrate (Sigma); rauwolscine 
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hydrochloride (Tocris, Ellisville, MO., USA); rosiglitazone maleate (maleate of 5-[[4-[2-
(methyl- 2-pyridinylamino)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione) (Kemprotec, 
Middlesbrough, UK). Stock solutions of rosiglitazone (10 mM) were prepared in ethanol. All 
other solutions were prepared in water. 
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Results 
In order to verify whether RSG modifies the prejunctional effect of AII, we compared 
the effect of noradrenalin release induced by AII in the presence and absence of RSG using 
electrical stimulation of the rat heart, which had previously been incubated with 3H-
noradrenaline. AII (1 – 100 nM) had no effect on the spontaneous efflux of 3H-noradrenaline 
and caused a concentration-dependent increase on the fractional release per shock (Fig. 1). The 
maximal increase on 3H-noradrenaline release induced by electrical stimulation in the presence 
of AII was 110±8% (n=18) in relation to control. RSG (3 µM) had no effect on the release of 
3H-noradrenaline induced by electrical stimulation. However the concentration-response curve 
to AII was shifted to the left in the presence of RSG. The potency of AII for the prejunctional 
effects expressed as pEC30% values was significantly increased by RSG at a concentration of 3 
µM (Table 1). 
 
 To verify whether RSG changes the postjunctional effect of AII, we compared the 
concentration-response curve for the contractile response of the rat aorta to AII in the presence 
and absence of RSG (Fig. 2). There was no significant shift to the left of this curve. The 
maximal tension caused by AII was similar in the absence (132±39 mN/g, n=5) and in the 
presence (129±35mN/g, n=5) of RSG. The potency of AII for contraction was not significantly 
changed by RSG (Table 1). 
 
To see if this effect was specific of AII, and not mediated by other receptors, we also 
compared the effect of noradrenalin release induced by the α2-adrenoceptor antagonist 
rauwolscine in the presence and absence of RSG using electrical stimulation of the rat heart, to 
conclude about the prejunctional responses to noradrenaline. RSG caused no shift of the 
concentration-response curve of rauwolscine. The pEC30% value of rauwolscine in the presence 
of RSG (3 µM) was not different from that obtained in its absence (Table 1). 
 
To look for the influence of RSG on the postjunctional effect of noradrenaline we 
determined concentration-response curves of the rat aorta to noradrenaline in the presence and 
absence of RSG. The pEC50 values in the presence and absence of RSG were not different 
(Table 1). The maximal effect of noradrenaline in the absence of RSG was 158±49 mN/g (n=4), 
in controls and of 149±48 mN/g (n=4) in the presence of RSG. 
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Discussion 
Our results confirm that RSG increased the facilitatory action of AII on noradrenaline 
release-enhancing effect in the terminal sympathetic nerves of the rat heart. This might be a 
possible explanation for the cardiovascular adverse effects of RSG, which could be mediated by 
the sympathetic system, leading to hypertension, acute myocardial infarction and cardiac heart 
failure.  As shown in figure 1, the concentration-response curve to AII in the presence of 
increasing concentrations of RSG was shifted to the left with increase of the maximum. This is 
in good agreement with Bastos et al. (2008), who reported that RSG and AT1-receptor 
antagonists had opposite effects on the prejunctional noradrenaline release-enhancing effect of 
AII. This means that while AT1-receptor antagonists reduced, RSG increased the facilitatory 
action of AII on noradrenaline release by sympathetic nerve stimulation.  
Our results concerning the postjunctional effect of AII show that RSG at the same 
concentration that potentiate the prejunctional effect of AII, does not shift the contractile 
concentration-response curve to AII (Fig. 2). The possibility that using a higher concentration of 
RSG may lead us to find a statistically significant postjunctional effect cannot be discarded.  
 
The difference between the pre and postjunctional results concerning the AII action in 
the presence and absence of RSG could be explained by a slight difference of the pre and 
postjunctional receptors of AII. It is well established that AII AT1 receptors are different pre- 
and postjunctionally and also that prejunctional and postjunctional AII receptors most probably 
belong to AT1B and AT1A subtypes, respectively. (Guimaraes and Pinheiro, 2005) 
 
Various studies have demonstrated that the vasoconstrictor effects  of AII result from a 
direct action on vascular smooth muscles (Helmer, 1964) and from an indirect action mediated 
by  facilitation of noradrenaline release from postganglionic sympathetic neurons (Guimaraes 
and Moura, 2001). These post and prejunctional effects of AII in the cardiovascular system are 
mediated by two types of receptors, AT1 and AT2 (Guimaraes and Pinheiro, 2005). AII produces 
virtually all its actions, like cardiovascular, neuronal, renal, endocrine and hepatic effects, by 
stimulation of AT1 receptors. These receptors mediate the vasoconstrictor effects, as well as 
vascular smooth muscle proliferation, aldosterone release and the regulation of the fluid-
electrolyte balance (Wong et al., 1991). On the other hand, the biological function of the AT2 
receptor remains unknown (Ozono et al., 1997). The AT1 receptor is sensitive to the reference 
compound losartan, whereas the AT2 receptor is sensitive to PD123177 and the related agent 
PD123319. A further subdivision of AT1 receptors into AT1A and AT1B subtypes is based on 
binding studies indicating a population of AT1 receptors for which PD123319 showed a high 
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affinity and losartan a lower affinity (Nap et al., 2004). Prejunctional receptors for AII most 
probably belong to AT1B subtypes. (Guimaraes and Pinheiro, 2005).  
 
AII, when acting on sympathetic neurons, induces an increase of exocytotic release of 
noradrenaline (Boehm and Kubista, 2002). This mediator acts on presynaptic AT1-receptors 
(Guimaraes et al., 2001). It was also established that AII requires ongoing α2-autoinhibition for 
the full extent of his noradrenaline release-enhancing effect (Trendelenburg et al., 2003). The 
facilitation of noradrenaline release caused by activation of AT1B-receptors requires an ongoing 
α2-autoinhibition (some degree of tonic autoinhibition) since the blockade of α2-autoreceptors 
attenuates the noradrenaline release enhancing effect of AII (Mota and Guimaraes, 2003). 
Therefore, in order to verify if the noradrenaline release-enhancing effect of RSG was specific 
for AII, the interactions between RSG and α2-antagonists on the prejunctional modulation of 
noradrenaline release were studied. Our results show that the release enhancing effects of 
rauwolscine were not changed in the presence of RSG 3 µM, when comparing with the control 
values (Table 1). These results indicate that RSG does not alter this alternative mechanism 
which enhances the release of RSG. We should be aware that there might be other mechanisms 
of presynaptic action of AII.  
 
Bearing the same objective in mind, we tested if the postjunctional effects of 
noradrenaline could be mediated by the presence and absence of RSG. As can be seen on table 
1, there is no difference in the rat aorta contraction that could be mediated by this drug. 
Therefore, the results concerning noradrenaline are coincident, pre and postjunctionally.  
Since we are studying acute actions of RSG in the rat heart and aorta, and 
thiazolidinediones are PPARγ agonists that act on the nucleus, we might consider that its actions 
were subacute or chronic. Peroxisome proliferator-activated receptors (PPAR) are nuclear 
receptors acting as transcription factors on numerous target genes after heterodimerization with 
the retinoid X receptor (Kahn and McGraw, 2010). PPARγ is mainly involved in fat cell 
differentiation and insulin sensitivity, and is expressed in smooth muscle cells and myocardium, 
although PPARγ is scarce in the latter. This could mean that RSG could not induce acute actions 
in our study. However, in transfected COS-7 cells, Tohgo et al (2003) found that angiotensin 
AT1a forms a stable receptor-β-arrestin complex, and activates a β-arrestin-bound pool of ERK2 
more efficiently than α1b and β2 adrenergic receptors, which form transient receptor-β-arrestin 
complexes. So, it is now established that, beyond the G-coupled pathways mediated by AII and 
noradrenaline, these two agonists also act through a second pathway, thus generating a powerful 
intracytoplasmatic signal. Studies also suggest that the existence of one or more mechanisms of 
ERK activation that do not require G protein activation, and that, like the β-arrestin-dependent 
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activation of ERK, leads to localized ERK activation outside of the cell nucleus. (Tohgo et al., 
2003) 
Also, in a cell-free assay the binding affinity of the AT1 receptor antagonists telmisartan 
and valsartan to the PPARγ is close to that of the PPARγ selective agonist RSG. This 
description of a PPARγ out-side the nucleus provide us the possibility that RSG can exert its 
noradrenaline enhancing effect acting on his well-known target. Otherwise, it will be hard to 
explain how in few minutes RSG is able to modify the release enhancing effect of AII acting on 
PPARγ localized in nucleus when its mechanisms supposes modifications in genes 
transcriptions (Storka et al., 2008). 
In conclusion, results show that RSG potentiates the noradrenaline-release enhancing 
effect of AII presinaptically, without changing the release-enhancing effect of α2- receptor 
antagonists. This might suggest a positive allosteric modulation of AII receptors by PPARγ 
agonists in sympathetic terminals. Our results also show that this concentration dependent effect 
of AII in the presence of RSG is more perceptible pre than postjunctionally, suggesting that the 
allosteric modulation is more pronounced at the AT1B receptor than at the AT1A receptor. These 
results might contribute to explain the mechanisms inherent to the adverse cardiovascular 
effects of RSG. 
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Legends 
Fig.1 Effects of RSG 3 µM in the presence of AII on noradrenaline release induced by electrical 
stimulation of the rat left ventricle slices incubated with 3H-noradrenaline. The effect of drugs 
was expressed as the ratio of the FR evoked by Sdrug over that evoked by Scontrol. Shown are 
means (n = 3-5) and best-fitting curves representing a 2-parameter logistic equation (software 
GraphpadPrism) 
 
Fig.2 Effects of RSG 3 µM in the presence of AII on the contractile force of the rat aorta. The 
effect of drugs was expressed in mN/g. Shown are means (n = 3-5) and best-fitting curves 
representing a 2-parameter logistic equation (software GraphpadPrism) 
 
  
 
Table 1: Influence of RSG on the potency of AII, noradrenaline and rauwolscine. 
 Prejunctional Effect Postjunctional Effect 
 Angiotensin II 
(pEC30%) 
Rauwolscine 
(pEC30%) 
Angiotensin II 
(pEC50) 
Noradrenaline 
(pEC50) 
Control      8.6 ± 0.1 8.7 ± 0.3 7.2 ± 0.4 6.9 ± 0.5 
Rosiglitazone 3µM      9.3 ± 0.3 * 8.9 ± 0.3 7.6 ± 0.5 7.0 ± 0.5 
 
Results are mean ± SEM (n=3-6) 
* p<0.05 vs control 
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